
Vicor Technologies, Inc. (OTCBB: VCRT)
Vicor represents a classic case in study for a successful Biotech Company. This is the perfect marriage of business experience with the development of a new medical test.
U.S. Military Requested this Test
First, it is important to understand this medical test was needed and DID NOT EXIST. There is a need in triage to understand which patient is in danger of Sudden Cardiac Arrest.
Vicor stepped up to the plate and accepted this challenge.
In terms of a Biotech Company about to take off, human clinical trials with the United States Military presents an enormous opportunity. In reading all that has been written about these trials I am convinced this presents incredible shareholder potential.
When you have military use of a product — civilian use is virtually simultaneous. Waiting for the official word from the U.S. Military provides and incredible opportunity to get a foothold in this Company.
My advice here — and what I do personally in my evaluations with these incredibly responsible companies is READ, READ READ BETWEEN THE LINES.
First - Understand the significance of the fact that this Company is in HUMAN TRIALS with the United States Military. Wow. This does not happen to every Biotech company. This fact alone is huge and if you have been reading my recent posts you understand why this Company is in HUMAN TRIALS with the United States Military. What they are doing provides a test that has the potential to become the gold standard in triage as a measure for Heart Rate Variability which is a predictor for SUDDEN CARDIAC ARREST.
Second – Read every word regarding these clinical trials. There is nothing that does not suggest these trials are NOT GOING WELL.
U.S. Military Clinical Trials
PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
Determined to minimize mortality rate of battlefield casualties, the U.S. Army Institute of Surgical Research has been working with Vicor’s PD2i-VS system through a research collaboration and has tested it against the best methodologies currently available. In extensive real-world testing involving several studies with data provided by the USAISR, the PD2i-VS™ has proven to be more predictive than all other compared technologies.
In Vicor’s most recent study with Army provided data, the PD2i-VS™ examined 325 civilian trauma injury victims, twenty of whom would later die of their injuries. Incredibly, the PD2i-VS™ correctly identified all twenty.
Even more importantly, of the twenty who died, conventional trauma triaging techniques had selected only six for lifesaving intervention in the field.
This suggests both that current trauma triage methods are woefully inadequate, and that the PD2i-VS™ is poised to make an extraordinary contribution to combat and trauma survival in the near future.
The very low PD2i™ values demonstrated in the chart at above right signify imminent risk of “crashing”, revealing dire need of aggressive medical intervention.
Clinical trials of the PD2i VS(TM) have been conducted under a collaborative agreement with the U.S. Army Institute of Surgical Research (USAISR) for the PD2i(TM) nonlinear algorithm and software as a diagnostic for in-field trauma triage AND was discussed at the American Heart Association’s Resuscitation Science Symposium in November 2009.
The American Heart Association’s Resuscitation Science Symposium (ReSS) is an international forum for fundamental, translational, clinical, and population scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury.
If the United States military has this product in clinical trials and is reporting on the product at a prestigious American Heart Association Conference — I am taking notice.
Experience Business Management Meets Medical Advancement
Once again, and forever and always with this Company, I want to put the science in perspective with the business management here.
We have FDA clearance for marketing as a measure of Heart Rate Variability. We have existing CPT codes physicians can use for the all important REIMBURSEMENT.
Now we have the U.S. Military reporting on this product to an American Heart Association convention. Not to mention we have this application in use in selected physician offices and WE HAVE PHYSICIANS AS THE EARLY ADOPTEE OF THIS COMPANY.
BioTech Company Advances Medicine and Creates Shareholder Value
This happens all the time — Biotech Companies make it big. They develop a needed product. They listened to the medical community at large and created a USABLE product. The product is marketed and medicine is once again advanced with the perfect marriage of experienced business leadership and science.
You are in the know.
Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com
Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.
Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.
Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.